New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 19, 2013
10:44 EDTXLRNAcceleron Pharma IPO indicated to open $18.50
News For XLRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
07:40 EDTXLRNAcceleron reports Q4 EPS (55c), consensus (23c)
Reports Q4 revenue $3.74M, consensus $9.58M.
March 1, 2015
12:24 EDTXLRNAcceleron reports new data from Dart study on dalantercept in patients with RCC
Acceleron Pharma reported new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma, RCC. The preliminary data from part 1 of the DART study were presented in an oral session at the American Society of Clinical Oncology, ASCO, 2015 Genitourinary Cancers Symposium held in Orlando, Florida on February 28. “These promising response rates and progression-free survival data suggest that the dual angiogenesis blockade of ALK1 and VEGFR signaling with dalantercept and axitinib may provide additive efficacy compared to VEGFR inhibitor therapy alone,” said Matthew Sherman, M.D., Chief Medical Officer of Acceleron. “The results from part 1 of this study provide encouraging evidence of the safety and activity of this combination of two distinct anti-angiogenic agents in previously treated patients with advanced RCC,” said Martin H. Voss, M.D., medical oncologist at Memorial Sloan Kettering Cancer Center and lead investigator for the trial. “We look forward to building on these results in the randomized part 2 of the ongoing DART trial.”
February 23, 2015
07:22 EDTXLRNSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use